secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001213900-23-039397
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences Q1 net loss $3.5M, revenue up 109% to $6.8M, cash dwindles
-------------------------------------------------------------------------------

- Net revenues $6.8M, up 109% YoY from $3.2M, driven by U.S. and MENA sales.
- Loss from operations improved to $1.2M from $3.1M loss in Q1 2022.
- Net loss $3.5M ($0.07 EPS) vs $1.5M ($0.03 EPS) a year ago, due to $3.7M other expense increase.
- Cash $1.8M at March 31, 2023, down from $2.0M; working capital insufficient, needs additional financing.
- Potential marketing approval for Endari in Saudi Arabia; fifth straight quarter of revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390023039397/0001213900-23-039397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390023039397/ea178443-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-039397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer